Sarcoma
Conditions
Keywords
adult angiosarcoma, adult epithelioid sarcoma, adult fibrosarcoma, adult leiomyosarcoma, adult liposarcoma, adult rhabdomyosarcoma, adult synovial sarcoma, stage III adult soft tissue sarcoma, adult malignant fibrous histiocytoma, adult neurofibrosarcoma, stage II adult soft tissue sarcoma, stage IV adult soft tissue sarcoma
Brief summary
RATIONALE: Drugs used in chemotherapy such as doxorubicin and ifosfamide use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors, such as pegfilgrastim, cause the body to make blood cells. It is not yet known whether doxorubicin alone is more effective with or without ifosfamide and pegfilgrastim in treating soft tissue sarcoma. PURPOSE: This randomized phase III trial is studying giving doxorubicin alone to see how well it works compared to giving doxorubicin together with ifosfamide and pegfilgrastim in treating patients with locally advanced or metastatic soft tissue sarcoma.
Detailed description
OBJECTIVES: * Compare the progression-free and overall survival of patients with locally advanced or metastatic soft tissue sarcoma treated with doxorubicin with vs without ifosfamide and pegfilgrastim as first-line therapy. * Compare the response in patients treated with these regimens. * Compare the treatment-related mortality of patients treated with these regimens. * Compare the toxicity of these regimens in these patients. OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to WHO performance status (0 vs 1), age group (less than 50 years of age vs 50 years of age and over), presence of liver metastases (yes vs no), histological grade (2 vs 3), and participating center. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive doxorubicin IV on day 1 (or IV continuously on days 1-3). * Arm II: Patients receive doxorubicin IV on days 1-3 and ifosfamide IV over 4 hours on days 1-4. Patients also receive pegfilgrastim subcutaneously on day 5. In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 8 weeks until disease progression and then every 12 weeks thereafter. PROJECTED ACCRUAL: A total of 450 patients will be accrued for this study within 4 years.
Interventions
Sponsors
European Organisation for Research and Treatment of Cancer - EORTC
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed soft tissue sarcoma * Locally advanced unresectable\* OR metastatic disease * High-grade (grade 2-3) disease according to the FNLCC grading system NOTE: \*Disease that could prove resectable (including pulmonary metastasectomy) after a response to chemotherapy is allowed * The following tumor types are eligible: * Malignant fibrous histiocytoma * Myxoid and round cell liposarcoma, pleomorphic liposarcoma, or dedifferentiated liposarcoma * Pleomorphic rhabdomyosarcoma * Synovial sarcoma * Myxofibrosarcoma, intermediate and high-grade * Fibrosarcoma * Leiomyosarcoma * Angiosarcoma * Malignant peripheral nerve sheath tumor * Epithelioid sarcoma * Alveolar rhabdomyosarcoma * Unclassifiable sarcoma, not otherwise specified * The following tumor types are not eligible: * Gastrointestinal stromal tumor * Mixed mesodermal tumor * Chondrosarcoma * Malignant mesothelioma * Neuroblastoma * Osteosarcoma * Ewing's sarcoma/primitive neuroectodermal tumor * Desmoplastic small round cell tumor * Embryonal rhabdomyosarcoma * Alveolar soft part sarcoma * Must have a measurable lesion with clinical evidence of progression within the past 6 weeks * Osseous lesions and pleural effusions are not considered measurable * No known or symptomatic CNS metastases PATIENT CHARACTERISTICS: Age * 18 to 60 Performance status * WHO 0-1 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count at least 2,000/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic * Bilirubin no greater than 1.8 mg/dL * Albumin at least 2.5 g/dL Renal * Creatinine no greater than 1.4 mg/dL OR * Creatinine clearance greater than 65 mL/min Cardiovascular * No history of cardiovascular disease Other * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception * No other severe medical illness * No psychosis * No other prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix or basal cell skin cancer * No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up schedule PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No prior chemotherapy for advanced or metastatic disease * Prior adjuvant chemotherapy allowed provided there was no disease progression within 6 months after completion of treatment Endocrine therapy * Not specified Radiotherapy * No prior radiotherapy to the sole index lesion Surgery * Not specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Response as assessed by RECIST criteria | — |
| Toxicity as assessed by CTC 2.0 | — |
| Treatment-related mortality | — |
Countries
Austria, Belgium, Canada, Denmark, France, Germany, Netherlands, Slovakia, Spain, Switzerland, United Kingdom
Outcome results
None listed